// App-Quantinova.ai

: PROGRAMMED DEATH-LIGAND 1 POSITIVE AND NON-EPITHELIAL SUBTYPE IN CIRCULATING TUMOR CELLS PREDICT LOCALLY ADVANCED PROSTATE CANCER PROGRESSION AND GUIDE THE IMMUNOTHERAPY AFTER SURGERY

Researchers

Presenter

  • Ke Li

Principal Investigators

  • Yiyuan Li

  • Ruji Wu

  • Yunhua Mao

  • Jianwen He

  • Yunhao Qing

  • Shuo Lu

  • Yean Huang

  • Jianguang Qiu

Medical Centers

  • N/A

Locations

  • N/A

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Prostate cancer

Biomarkers

  • Circulating tumor cells

  • Programmed death-ligand 1

Drug/Treatment

  • hRPC

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved